A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults

NCT00562484 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

7500

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: CSL Limited Influenza Vaccine
BIOLOGICAL: Placebo

Sponsor

Seqirus